Twice-Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
95 transplants fulfilled the inclusion criteria
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
None of the patients had to discontinue micafungin due to safety or tolerability concerns. [CONCLUSIONS] Twice-weekly IV micafungin is a safe and effective option as antifungal prophylaxis for children undergoing HSCT.
[BACKGROUND] Children undergoing hematopoietic stem cell transplantation are at increased risk of developing invasive fungal infection.
- 표본수 (n) 5
APA
Ab Rahman S, Chiew XY, et al. (2026). Twice-Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation.. Pediatric transplantation, 30(3), e70296. https://doi.org/10.1111/petr.70296
MLA
Ab Rahman S, et al.. "Twice-Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation.." Pediatric transplantation, vol. 30, no. 3, 2026, pp. e70296.
PMID
41820822 ↗
Abstract 한글 요약
[BACKGROUND] Children undergoing hematopoietic stem cell transplantation are at increased risk of developing invasive fungal infection. Micafungin is an echinocandin with broad-spectrum antifungal properties. Recent trials have reported on the efficacy of intermittent daily dosing of micafungin for fungal prophylaxis in pediatric patients undergoing transplantation, with success rates of 76%-99%, success defined as absence of proven, probable, or possible invasive fungal infection. We implemented a twice-weekly micafungin regimen as antifungal prophylaxis in our unit.
[PATIENTS AND METHODS] One hundred consecutive transplants performed between May 2018 and February 2024 were analyzed. Micafungin prophylaxis was dosed at 3-5 mg/kg daily given twice weekly from Day 0 till stable neutrophil engraftment, after which oral fluconazole was prescribed till Day +100. Fungal infection status was evaluated by radiological procedures and cultures from blood or sterile body sites as clinically indicated. The primary endpoint of the study was the evaluation of efficacy; secondary endpoints were safety and tolerability.
[RESULTS] Ninety three patients who underwent 95 transplants fulfilled the inclusion criteria. Underlying diagnoses were: leukemia (47), inborn errors of immunity (11), other malignancies (11), hemoglobinopathy (8), and others (16). There were no proven or probable fungal infections. Seventeen patients (18%) required change from prophylaxis to empirical antifungal treatment for persistent fever (n = 5) and possible fungal infections, mainly oesophagitis (n = 8). All patients who failed micafungin prophylaxis received allogeneic transplants, and HLA-haploidentical was the majority (14/17). None of the patients had to discontinue micafungin due to safety or tolerability concerns.
[CONCLUSIONS] Twice-weekly IV micafungin is a safe and effective option as antifungal prophylaxis for children undergoing HSCT.
[PATIENTS AND METHODS] One hundred consecutive transplants performed between May 2018 and February 2024 were analyzed. Micafungin prophylaxis was dosed at 3-5 mg/kg daily given twice weekly from Day 0 till stable neutrophil engraftment, after which oral fluconazole was prescribed till Day +100. Fungal infection status was evaluated by radiological procedures and cultures from blood or sterile body sites as clinically indicated. The primary endpoint of the study was the evaluation of efficacy; secondary endpoints were safety and tolerability.
[RESULTS] Ninety three patients who underwent 95 transplants fulfilled the inclusion criteria. Underlying diagnoses were: leukemia (47), inborn errors of immunity (11), other malignancies (11), hemoglobinopathy (8), and others (16). There were no proven or probable fungal infections. Seventeen patients (18%) required change from prophylaxis to empirical antifungal treatment for persistent fever (n = 5) and possible fungal infections, mainly oesophagitis (n = 8). All patients who failed micafungin prophylaxis received allogeneic transplants, and HLA-haploidentical was the majority (14/17). None of the patients had to discontinue micafungin due to safety or tolerability concerns.
[CONCLUSIONS] Twice-weekly IV micafungin is a safe and effective option as antifungal prophylaxis for children undergoing HSCT.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.